To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL PLC - Directorate changes

Release Date: 24/07/2019 15:50
Code(s): MEI     PDF:  
 
Wrap Text
Directorate changes

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, or the “Company” or the “Group”)

24 July 2019

DIRECTORATE CHANGES

DR EDWIN HERTZOG: INTENTION TO RETIRE AS CHAIRMAN

Mediclinic announces that Dr Edwin Hertzog, 69, has indicated his intention to retire as Chairman at
the conclusion of the Annual General Meeting in July 2020. A search for Dr Hertzog’s successor as
Chairman will be initiated in due course and the Board will provide an update when available.

Desmond Smith, Senior Independent Director said:

“On behalf of the Board, I would like to thank Dr Hertzog for his commitment to Mediclinic throughout
his 36 year tenure at management level and on the Board. Dr Hertzog has been instrumental in
Mediclinic’s growth from a domestic private hospital operator in South Africa to an international private
healthcare services group. The Board and I wish Dr Hertzog well in his planned retirement.”

Dr Edwin Hertzog, Chairman of Mediclinic, commented:

“Following my many years at Mediclinic, the time has come for me to retire as Chairman. During my
time at Mediclinic, I have thoroughly enjoyed working with many talented people who have helped to
grow an international business that puts patients first, providing world-class care. I have great
confidence that the team, Mediclinic’s solid positioning and the efficient functioning of the Company will
ensure an attractive future for all its stakeholders”.

About Mediclinic International plc

Mediclinic is an international private healthcare services group, established in South Africa in 1983,
with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab
Emirates.

The Group’s core purpose is to enhance the quality of life by way of appropriate healthcare services.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the
continuum of care in such a way that the Group will be regarded as the most respected and trusted
provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare
in each of its markets.

Mediclinic comprises 77 hospitals, five sub-acute hospitals, 13 day case clinics and 21 outpatient
clinics. Hirslanden operates 18 hospitals, two day case clinics and three outpatient clinics in
Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operates 52 hospitals,
five sub-acute hospitals and 9 day case clinics with more than 8 500 inpatient beds; and Mediclinic
Middle East operates seven hospitals, two day case clinics and 21 outpatient clinics with more than
900 inpatient beds in the United Arab Emirates.

The Company’s primary listing is on the London Stock Exchange (“LSE”) in the United Kingdom, with
secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group
based in the United Kingdom and listed on the LSE.
For further information, please contact:

Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Brett Pollard/Debbie Scott – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE Ltd sponsor: Rand Merchant Bank (A division of FirstRand Bank Ltd)
NSX sponsor: Simonis Storm Securities (Pty) Ltd

Date: 24/07/2019 03:50:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Email this JSE Sens Item to a Friend.

Share This Story